Vir Biotechnology (VIR) Other Non-Current Liabilities (2018 - 2026)

Vir Biotechnology has reported Other Non-Current Liabilities for 9 years, with the latest figure at $19.4 million in Q1 2026.

• Quarterly Other Non-Current Liabilities rose 31.09% year-over-year to $19.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.4 million (up 31.09% YoY) and the FY2025 annual result came in at $21.6 million, up 48.03% from the prior year.
• Other Non-Current Liabilities eased to $19.4 million in Q1 2026 per VIR's latest filing, from $21.6 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $28.5 million in Q2 2022 and troughed at $7.2 million in Q3 2022.
• A 5-year average of $16.3 million and a median of $14.2 million in 2024 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities soared 638.52% in 2022, then plunged 57.5% in 2023.
• Over 5 years, Other Non-Current Liabilities stood at $24.9 million in 2022, then climbed by 4.1% to $26.0 million in 2023, then tumbled by 43.85% to $14.6 million in 2024, then surged by 48.03% to $21.6 million in 2025, then retreated by 10.01% to $19.4 million in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $19.4 million, $21.6 million, and $13.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.